What is Sight Sciences?
Sight Sciences Inc. is dedicated to advancing ophthalmic care through innovative medical devices. The company focuses on developing and commercializing both surgical and nonsurgical technologies designed to address a range of eye diseases. Its commitment to innovation has positioned it as a key player in the medical device sector, aiming to improve patient outcomes and treatment efficacy. The company's strategic funding rounds reflect its ambition to scale its operations and further its research and development efforts.
How much funding has Sight Sciences raised?
Sight Sciences has raised a total of $181.9M across 8 funding rounds:
Series A
$6.9M
Series B
$7M
Series C
$10M
Series D
$31M
Stock Offering
$30M
Debt
$2M
Series E
$30M
Debt
$65M
Series A (2015): $6.9M with participation from Scientific Health Development Partners and Allegro Investment Fund
Series B (2016): $7M led by Scientific Health Development Partners, Allegro Investment Fund, and Hicks Equity Partners
Series C (2017): $10M supported by Allegro Investment Fund
Series D (2019): $31M, investors not publicly disclosed
Stock Issuance/Offering (2020): $30M backed by D1 Capital Partners
Debt (2020): $2M with participation from PPP
Series E (2021): $30M led by D1 Capital Partners
Debt (2024): $65M supported by Hercules Capital
Key Investors in Sight Sciences
Hercules Capital
Hercules Capital is a specialty finance company focused on providing senior secured venture growth loans to high-growth, innovative venture capital-backed companies in a broad variety of technology, life sciences and sustainable and renewable technology industries. Hercules Capital is headquartered in Palo Alto, California.
D1 Capital Partners
D1 Capital Partners is an investment firm that has participated in multiple funding rounds for Sight Sciences, indicating a strong belief in the company's potential and strategic direction.
Allegro Investment Fund
Allegro Investment Fund is a private investment vehicle that provides strategic and financial support to talented, entrepreneurial businesses, aiming to create a lasting, positive impact. With 25 years of experience and $750 million under management, the fund focuses on investments ranging from $10 million to $50 million.
What's next for Sight Sciences?
With its latest round of major strategic investment, Sight Sciences is poised for accelerated growth and further innovation in the ophthalmic device market. The company's trajectory, marked by consistent capital raises since its inception, suggests a strong focus on expanding its product portfolio and market reach. Future endeavors will likely involve scaling manufacturing, enhancing commercialization efforts, and potentially exploring new therapeutic areas within ophthalmology. The sustained backing from investors indicates confidence in Sight Sciences' long-term vision and its capacity to deliver impactful solutions.
See full Sight Sciences company page
